Track record

Three $1B+ brands.
The full record.

Turnarounds, launches and growth acceleration. Twenty-plus years in commercial leadership, including Novartis from 2012 to Feb 2026, leading P&Ls up to $2.2B. Career results from roles at Novartis, not Scalar Group client results.

$1B+Kisqali, oncology: failed launch turned market leader, now $3B+ in the U.S.
$2.2BKesimpta, neuroscience: growing 50% while gaining share
$1B+Promacta, hematology: from $400M to market leader, patent life +2 years
1 deal executed$3B+ inorganic mandate
10licensing and distribution agreements negotiated and signed

Most recent role · Nov 2024–Feb 2026

Vice President, Head of Enterprise Growth & Innovation, Novartis U.S.

I led growth and innovation for Novartis U.S.: growth strategy, AI initiatives and M&A to grow the U.S. business. The mandate was to find inorganic opportunities supporting more than $3B of additional U.S. revenue by 2028. I took two deals to the final stage and executed one under a $3B+ U.S. inorganic growth mandate. It is the work I now bring to clients: where the next growth comes from, which bets to make, and how to get the deal done.

Selected results

Mandate, what I did, result.

Oncology · U.S.

$1B+

market leader · now $3B+

Executive Director, Product Strategy Lead / GM, Oncology
2022–2023

Turning Kisqali around: from a failed launch to market leader, past $1B (now over $3B in the U.S.)

Mandate: Lead product strategy for an oncology brand, with 30+ cross-functional leaders and a 200+ person sales force (co-led).
What I did: Reframed the strategy around differentiation and new-prescriber acquisition, moved investment toward higher-return tactics and strengthened KPI-based governance.
Result: Turned a failed launch into the market leader, passing $1B in sales under my leadership (now over $3B in the U.S.). Market share reached approximately 50%, and the prescriber base tripled.

Neuroscience · U.S.

$2.2B

brand growing 50% · market share gained · ~300 people

Vice President & General Manager, Neuroscience
2023–2024

Accelerating Kesimpta: bringing new patients back to growth at $2.2B

Mandate: Lead a $2.2B U.S. business with approximately 300 employees, owning strategy, investment allocation, talent and cross-functional execution.
What I did: Rebuilt the leadership team, talent, culture, decision rights and execution governance. Aligned Sales, Marketing, Market Access, Medical, Global Commercial and R&D around focused workstreams, KPIs and launch readiness, while preparing four pipeline assets and indications.
Result: The business was growing, but new-patient starts were slipping and putting long-term growth at risk. I led the brand back to new-patient growth, reaching $2.2B, up 50% versus the prior year.

Hematology · U.S.

$1B+

brand taken from $400M · patent life extended 2 years

Executive Director, Head of Marketing, Hematology
2020–2022

Accelerating Promacta to market leader in its final years before patent expiry

Mandate: Lead marketing for a hematology franchise in a competitive market, in the five years before patent expiry.
What I did: Found new growth levers, launched two new indications and championed a two-year patent-life extension.
Result: Accelerated the brand to market leadership, from $400M past $1B, and extended its patent life by 2 years. More than $130M in annual incremental sales and approximately 10 points of market share gained in two years; the extension was estimated to add more than $2B in revenue.

Enterprise growth · BD & M&A

1 deal executed

$3B+ inorganic mandate

Vice President, Head of Enterprise Growth & Innovation, Novartis U.S.
Nov 2024–Feb 2026

Finding the deals behind a $3B+ growth target

Mandate: Lead growth and innovation for Novartis U.S., including AI initiatives and M&A to grow the U.S. business. Identify inorganic opportunities to support more than $3B of additional U.S. enterprise revenue by 2028, leading a cross-therapeutic-area team and an advisory board.
What I did: Screened thousands of assets and prioritized approximately 30 high-potential targets. Also led innovation work, including incubation, operating-model redesign and an assessment of AI-enabled technologies for commercial effectiveness.
Result: Took two deals to the final stage and executed one under a $3B+ U.S. inorganic growth mandate.

International

Europe and Latin America.

Before my U.S. roles, I led brands in Europe (Spain) for Novartis, and P&Ls and businesses across Latin America for Novartis and Sandoz.

Latin America · Sandoz

$400M

P&L across several therapeutic areas · 500 reps · 7 country heads

Commercial Head, Latin America, Sandoz
2016–2018

Running a $400M P&L across several therapeutic areas in Latin America

Mandate: As Commercial Head, Latin America, for Sandoz, lead a $400M P&L across several therapeutic areas (oncology, neuroscience, cardiometabolic, anti-infectives, transplant, HIV, pain and ophthalmology), with 500 sales representatives and seven country heads.
What I did: Expanded profitability through mix, pricing discipline, sales-force efficiency and marketing productivity. Integrated $150M of products into a new promotional model, launching four promotional lines and hiring 200.
Result: Double-digit sales growth for two consecutive years.

Neuroscience · Spain2013
Managed approximately $90M in mature neuroscience brands: generic-entry defense, divestments, lifecycle initiatives and a brand-extension launch.
Ophthalmology · Spain2012
Managed approximately $10M in ophthalmology public accounts, delivered 4% growth and developed the private-market opportunity.

More of the record

Launches, access, deals and the field.

Cardiovascular · U.S.2019–2020
Led commercial strategy and a full field-force restructuring (~500 hires); the business unit delivered approximately 40% year-over-year net-sales growth. Introduced digital promotion and supported early launch planning for a new cardiovascular medicine.
Market access · payer contractingCareer-long
I personally signed risk-based payer contracts in Spain (ophthalmology) early in my career; over the past eight years, I led the Market Access teams that negotiated payer contracts for every brand I led, including outcomes- and risk-based agreements.
Business development · Latin America2014–2015
Negotiated and signed 10 licensing and distribution agreements, supporting sustained double-digit growth and a regional margin turnaround.
Investors2026
Advisor to Crane Venture Partners: evaluated 12 healthcare and biotech opportunities. Co-founded an independent-sponsor PE platform that acquires and scales founder-led businesses.

Therapeutic areas: oncology, hematology, neuroscience, neuroimmunology, cardiometabolic and ophthalmology, plus other specialty and primary-care markets. Markets: United States, Latin America, Spain, France and the United Kingdom.

30-minute call with Emilio

Want this experience on your problem? Book a 30-minute call.

Tell me where the business is and what has to happen next. No obligation, and if Scalar isn't the right fit, I'll say so.

Book a 30-minute call with Emilio Send a message

I reply personally.

Three $1B+ brands. The full record.